AASDL 2012: A shift to direction action in hepatitis C?
This article was originally published in Scrip
Executive Summary
New antivirals that that allow for interferon-sparing regimens for treating hepatitis C drugs are set to dominate pharmaceutical thinking at this year’s meeting of the American Association for the Study of Liver Diseases in Boston on 9-13 November.